A number of pharmacological inhibitors have now reached clinical trials for severe plaque psoriasis, acute pancreatitis, asthma and coronavirus disease 2019 (COVID-19)-associated severe pneumonia (Stauderman, 2018; Miller et al., 2020), which highlights the therapeutic potential of the ORAI1 channel inhibitors and the tolerability of the ORAI1 inhibitors in patients. This evidence concerns the gene ORAI1 and acute pancreatitis.